Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lafurtidine vs rebamipide for gastric mucosal lesions in acute/chronic gastritis exacerbation
ChiCTR2300070452Phase 4Not yet recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of lafutidine in acute gastritis and chronic gastritis (2 arms), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoint: Gastric mucosal condition. Planned start May 2023; status: not yet recruiting.
02
Drugs
lafutidine
03
Conditions
acute gastritischronic gastritis
Beyond the preview
Go deeper on ChiCTR2300070452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070452.